ArticleObstetrics and gynecology2018
Prenatal Treatment and Outcomes of Women With Opioid Use Disorder.
Article in Obstetrics and gynecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- The comparative effects of prenatal exposure to methadone versus buprenorphine for opioid use disorder on neonatal outcomes: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2026Pooled it
- Systematic Review: Polysubstance Prevalence Estimates Reported during Pregnancy, US, 2009-2020.Maternal and child health journal · 2023Pooled it
- Design, implementation, and evaluation of neonatal abstinence syndrome care management web application: a multimethod study.Scientific reports · 2026Trial
- Overdose risk profiles in pregnancy: Latent class analysis of pregnant individuals with opioid use disorder.Journal of substance use and addiction treatment · 2025Article
- Factors associated with medications for opioid use disorder (MOUD) treatment success during the pregnancy and postpartum periods: A scoping review.Drug and alcohol dependence · 2024Article
- Development of an Educational Brochure about Treatment Options for Pregnant Women with Opioid Use Disorders.Pharmacy (Basel, Switzerland) · 2024Article
- Advances in animal models of prenatal opioid exposure.Trends in neurosciences · 2024Review
- Article
- Prenatal methadone exposure selectively alters protein expression in primary motor cortex: Implications for synaptic function.Frontiers in pharmacology · 2023Article
- Article
- Perinatal Fentanyl Exposure Leads to Long-Lasting Impairments in Somatosensory Circuit Function and Behavior.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- The MATernaL and Infant NetworK to Understand Outcomes Associated with Treatment of Opioid Use Disorder During Pregnancy (MAT-LINK): Surveillance Opportunity.Journal of women's health (2002) · 2020Article
- Opioids affect the fetal brain: reframing the detoxification debate.American journal of obstetrics and gynecology · 2019Article
- Management of the Cardiovascular Complications of Substance Use Disorders During Pregnancy.Current treatment options in cardiovascular medicine · 2019Review
- Pregnancy-Associated Death in Utah: Contribution of Drug-Induced Deaths.Obstetrics and gynecology · 2019Article
- Medication for Addiction Treatment and Postpartum Health Care Utilization Among Pregnant Persons With Opioid Use Disorder.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo describe the characteristics, treatment, and outcomes of pregnant women with opioid use disorder.
methodsWomen attending an obstetric and addiction recovery clinic in Boston from 2015 to 2016 were enrolled in a prospective cohort study and followed through delivery (N=113). Buprenorphine or methadone was initiated clinically. The Addiction Severity Index was administered at enrollment. Prenatal and delivery data were systematically abstracted from medical charts.
resultsMost women in the cohort were non-Hispanic white (80.5%) with a mean age of 28 years. Few women were married (8.9%). More than half of the cohort had been incarcerated, 29.2% had current legal involvement, and 15.0% generally had unstable housing. A majority (70.8%) were infected with hepatitis C and histories of sexual (56.6%) and physical (65.5%) abuse were prevalent. Regular substance used included heroin (92.0%), injection heroin (83.2%), other opioids (69.0%), marijuana (73.5%), alcohol (56.6%), and cocaine (62.8%). Fifty-nine women (52.2%) were treated initially with prenatal buprenorphine and 54 (47.8%) with methadone; 49.6% also were taking concomitant psychotropic medications. Employment (0.766±0.289) and psychologic (0.375±0.187) Addiction Severity Index scores were the highest, indicating the most severe problems in these areas. Opioid use relapse did not differ by treatment (44.7% overall). Thirteen (22.5%) of 59 women treated with buprenorphine transitioned to methadone mainly because of positive opioid screens. Overall, 23.0% (n=26) of the cohort discontinued clinical care. The number of pregnancy losses was small (three therapeutic abortions, four miscarriages, one stillbirth), with an overall live birth rate of 90.8% (95% CI 82.7-95.9).
conclusionThese data on the social circumstances, substance use, treatment, and treatment outcomes of pregnant women with opioid use disorder may help clinicians to understand and treat this clinically complex population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.